Latest Health News

Cleo Diagnostics has identified a significantly larger U.S. patient population for its pre-surgical ovarian cancer test, expanding its commercial opportunity ahead of next year’s market entry.

Noumi Limited reported a 13% rise in adjusted operating EBITDA for FY25, driven by strong growth in its Milklab plant-based milk brand, while preparing for a significant convertible note maturity in 2027.

Amcor’s first quarter fiscal 2026 results showcase strong growth driven by the Berry Global acquisition, with sales up 68% and synergies exceeding expectations. The company also raised its dividend and reaffirmed its full-year guidance.

Larvotto Resources has appointed PYBAR Mining Services to undertake extensive underground development at its Hillgrove Antimony-Gold Project, paving the way for production to commence in 2026.

National Australia Bank reported a modest rise in underlying profit for FY25, driven by robust revenue and volume growth in the second half, alongside continued technology modernization and sustainability progress.

4DMedical has responded to ASX queries over its FY2025 financial report, clarifying assumptions behind intangible asset valuations and addressing the auditor’s qualified opinion.

Mesoblast is set to meet the FDA in December to discuss compelling Phase 3 data showing its cell therapy rexlemestrocel-L may significantly reduce opioid use in chronic low back pain patients. This meeting could mark a pivotal step in addressing the US opioid crisis through innovative regenerative medicine.

Stakk Limited has reported a record-breaking $575,000 in revenue for October 2025, marking a staggering 146% increase from the previous month and nearly 9,500% growth year-over-year.

BPH Global has locked in a six-month exclusive agreement to evaluate a proprietary ginseng-based formulation aimed at enhancing male vitality, signaling a strategic push into Traditional Chinese Medicine-inspired wellness products.

TPG Telecom has announced a substantial special dividend and capital reduction totaling approximately AUD 3 billion, pending shareholder approval at the upcoming EGM.

Nanosonics Limited has announced a $20 million on-market share buy-back program for FY26, underscoring its robust financial health and confidence in future growth driven by new product innovations.

CSL Limited’s latest Capital Markets Day presentation highlights CSL Seqirus’s strategic positioning to capitalize on a recovering US influenza vaccine market and global growth opportunities.